SUPERNUS PHARMACEUTICALS, INC.
SUPN · Pharmaceutical Preparations · 58.0M shares · +1%/yr ↑ shares · EDGAR filings ↗
Reference price $49.55 · est. market cap ~$2.9B — last insider sale, 2026-03-18 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C63Diversified commercial CNS pharma with strong cash generation; current-year loss is acquisition-driven, not operational distress.
Strengths
- $719M revenue, 90% gross margin (84th pct), and positive FCF $46M (86th pct)
- Diversified portfolio with Qelbree growing 26% and new launches (ONAPGO, ZURZUVAE)
- High-percentile ROA/ROE ranks (83rd/72nd) despite headline losses
Risks
- GAAP net loss (net margin -5.4%) and earnings down 152% (7th pct), largely from the Sage acquisition
- Generic erosion of legacy products (Oxtellar/Trokendi XR) and ONAPGO supply constraints
- Pipeline setbacks (SAGE-718 failed multiple cognition trials); integration/contingent-value risk
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -5.4%)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Strong balance sheetStrong balance sheet — $128M cash & investments
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC +2 more (as of 2026-03-31)
- Insider sellingInsider selling — 17 open-market sale(s) by 7 insider(s) (cluster of 7 insiders, ~$9M, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-09 — PHASE3 · Attention-Deficit/Hyperactivity Disorder
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
89.6%
Operating margin
-8.7%
Net margin
-5.4%
Return on equity
-3.6%
Return on assets
-2.7%
Revenue growth (QoQ)
-1.8%
Net-income growth
-152.2%
Current ratio
1.9×
Free cash flow
$46M
EBITDA
$29M
Tangible book value
$367M
Cash & investments
$128M
Stock comp / revenue
4.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-18 | Bhatt Padmanabh P. | Option exercise | 7.2K | $39.40 |
| 2026-03-18 | Bhatt Padmanabh P. | Sell | 6.8K | $49.55 |
| 2026-03-18 | Bhatt Padmanabh P. | Sell | 412 | $50.48 |
| 2026-03-17 | Bhatt Padmanabh P. | Option exercise | 12K | $36.75 |
| 2026-03-17 | Bhatt Padmanabh P. | Sell | 28K | $49.95 |
| 2026-03-17 | Bhatt Padmanabh P. | Option exercise | 15K | $38.60 |
| 2026-03-17 | Bhatt Padmanabh P. | Sell | 22K | $50.73 |
| 2026-03-17 | Bhatt Padmanabh P. | Option exercise | 23K | $39.40 |
| 2026-03-16 | Bhatt Padmanabh P. | Option exercise | 4.2K | $29.61 |
| 2026-03-16 | Bhatt Padmanabh P. | Option exercise | 18K | $32.20 |
| 2026-03-16 | Bhatt Padmanabh P. | Option exercise | 5.0K | $27.94 |
| 2026-03-16 | Bhatt Padmanabh P. | Sell | 34K | $50.18 |
| 2026-03-16 | Bhatt Padmanabh P. | Sell | 16K | $50.49 |
| 2026-03-16 | Bhatt Padmanabh P. | Option exercise | 23K | $36.75 |
| 2026-03-13 | Khattar Jack A. | Other | 12K | — |
| 2026-03-13 | Khattar Jack A. | Other | 12K | — |
| 2026-03-13 | Khattar Jack A. | Sell | 24K | $50.09 |
| 2026-03-13 | Khattar Jack A. | Sell | 11K | $51.00 |
| 2026-03-13 | Khattar Jack A. | Sell | 120 | $51.75 |
| 2026-03-12 | Hudson Frederick M. | Sell | 5.4K | $50.61 |
| 2026-03-10 | Horich William Todd | Sell | 4.4K | $55.00 |
| 2026-03-09 | Mottola Frank | Sell | 1.6K | $53.65 |
| 2026-03-09 | Horich William Todd | Sell | 4.4K | $54.00 |
| 2026-03-06 | Horich William Todd | Option exercise | 3.8K | — |
| 2026-03-06 | Horich William Todd | Option exercise | 1.1K | — |
| 2026-03-06 | Horich William Todd | Tax withheld | 521 | $54.73 |
| 2026-03-06 | Khattar Jack A. | Option exercise | 39K | — |
| 2026-03-06 | Khattar Jack A. | Tax withheld | 17K | $54.73 |
| 2026-03-06 | DEC TIMOTHY C | Option exercise | 3.0K | — |
| 2026-03-06 | DEC TIMOTHY C | Tax withheld | 1.4K | $54.73 |
| 2026-03-06 | DEC TIMOTHY C | Option exercise | 3.0K | — |
| 2026-03-06 | DEC TIMOTHY C | Tax withheld | 1.4K | $54.73 |
| 2026-03-06 | GEMAYEL GEORGES | Option exercise | 7.9K | $25.30 |
| 2026-03-06 | GEMAYEL GEORGES | Sell | 8.8K | $53.00 |
| 2026-03-06 | Horich William Todd | Tax withheld | 1.7K | $54.73 |
| 2026-03-06 | Horich William Todd | Tax withheld | 1.2K | $54.73 |
| 2026-03-06 | Mottola Frank | Option exercise | 3.8K | — |
| 2026-03-06 | Mottola Frank | Tax withheld | 1.8K | $54.73 |
| 2026-03-06 | Horich William Todd | Option exercise | 2.6K | — |
| 2026-03-05 | GEMAYEL GEORGES | Sell | 10K | $53.71 |
| 2026-02-25 | Mottola Frank | Tax withheld | 977 | $50.69 |
| 2026-02-25 | Bhatt Padmanabh P. | Grant | 1.2K | — |
| 2026-02-25 | Bhatt Padmanabh P. | Tax withheld | 650 | $50.69 |
| 2026-02-25 | DEC TIMOTHY C | Grant | 2.5K | — |
| 2026-02-25 | Rubin Jonathan | Grant | 1.2K | — |
| 2026-02-25 | Rubin Jonathan | Tax withheld | 675 | $50.69 |
| 2026-02-25 | DEC TIMOTHY C | Tax withheld | 1.3K | $50.69 |
| 2026-02-25 | Mottola Frank | Grant | 1.9K | — |
| 2026-02-24 | Bhatt Padmanabh P. | Grant | 1.1K | — |
| 2026-02-24 | Rubin Jonathan | Grant | 1.1K | — |
| 2026-02-24 | Rubin Jonathan | Tax withheld | 603 | $51.35 |
| 2026-02-24 | Rubin Jonathan | Grant | 750 | — |
| 2026-02-24 | Rubin Jonathan | Tax withheld | 369 | $50.86 |
| 2026-02-24 | Rubin Jonathan | Grant | 1.2K | — |
| 2026-02-24 | Rubin Jonathan | Tax withheld | 671 | — |
| 2026-02-24 | Mottola Frank | Grant | 1.1K | — |
| 2026-02-24 | Mottola Frank | Tax withheld | 603 | $51.35 |
| 2026-02-24 | Mottola Frank | Grant | 750 | — |
| 2026-02-24 | Mottola Frank | Tax withheld | 368 | $50.86 |
| 2026-02-24 | Mottola Frank | Grant | 1.2K | — |
| 2026-02-24 | Mottola Frank | Tax withheld | 670 | $50.86 |
| 2026-02-24 | Barlow Carrolee | Grant | 4.5K | — |
| 2026-02-24 | Bhatt Padmanabh P. | Tax withheld | 581 | $51.35 |
| 2026-02-24 | Bhatt Padmanabh P. | Grant | 750 | — |
| 2026-02-24 | Bhatt Padmanabh P. | Tax withheld | 354 | $50.86 |
| 2026-02-24 | Bhatt Padmanabh P. | Grant | 1.2K | — |
| 2026-02-24 | Bhatt Padmanabh P. | Tax withheld | 646 | $50.86 |
| 2026-02-24 | Hudson Frederick M. | Grant | 4.5K | — |
| 2026-02-24 | GEMAYEL GEORGES | Grant | 4.5K | — |
| 2026-02-24 | DEC TIMOTHY C | Grant | 1.1K | — |
| 2026-02-24 | DEC TIMOTHY C | Tax withheld | 603 | $51.35 |
| 2026-02-24 | DEC TIMOTHY C | Grant | 500 | — |
| 2026-02-24 | DEC TIMOTHY C | Tax withheld | 242 | $50.86 |
| 2026-02-24 | DEC TIMOTHY C | Grant | 3.0K | — |
| 2026-02-24 | DEC TIMOTHY C | Tax withheld | 1.5K | $50.86 |
| 2026-02-24 | NEWHALL CHARLES W III | Grant | 4.5K | — |
| 2026-02-23 | GEMAYEL GEORGES | Option exercise | 15K | $12.98 |
| 2026-02-19 | Sensenig Bethany | Sell | 1.2K | $50.31 |
| 2026-02-19 | Sensenig Bethany | Option exercise | 4.5K | — |
| 2026-02-19 | Sensenig Bethany | Sell | 3.3K | $51.27 |
| 2026-01-09 | Hudson Frederick M. | Option exercise | 15K | $12.98 |
| 2025-12-19 | Mottola Frank | Sell | 5.0K | $50.22 |
| 2025-12-19 | Mottola Frank | Option exercise | 5.0K | $39.40 |
| 2025-12-19 | Mottola Frank | Option exercise | 15K | $25.30 |
| 2025-12-19 | Mottola Frank | Sell | 15K | $50.47 |
| 2025-12-18 | Bhatt Padmanabh P. | Option exercise | 1.5K | — |
| 2025-12-18 | Bhatt Padmanabh P. | Sell | 710 | $44.44 |
| 2025-11-21 | NEWHALL CHARLES W III | Option exercise | 15K | $12.98 |
| 2025-10-09 | NEWHALL CHARLES W III | Sell | 24K | $50.73 |
| 2025-10-09 | Khattar Jack A. | Option exercise | 81K | $25.30 |
| 2025-10-09 | Khattar Jack A. | Sell | 58K | $50.55 |
| 2025-10-09 | Khattar Jack A. | Sell | 1.5K | $51.46 |
| 2025-10-09 | NEWHALL CHARLES W III | Sell | 1.2K | $51.55 |
| 2025-10-02 | Khattar Jack A. | Option exercise | 2.3K | $25.30 |
| 2025-10-02 | Khattar Jack A. | Option exercise | 20K | — |
| 2025-10-02 | Khattar Jack A. | Tax withheld | 7.8K | $46.21 |
| 2025-10-02 | Khattar Jack A. | Option exercise | 19K | — |
| 2025-10-02 | Khattar Jack A. | Tax withheld | 7.5K | $46.21 |
| 2025-10-02 | Khattar Jack A. | Sell | 1.9K | $48.06 |
| 2025-10-01 | Khattar Jack A. | Option exercise | 54K | $25.30 |
| 2025-10-01 | Khattar Jack A. | Sell | 40K | $48.07 |
| 2025-09-30 | Khattar Jack A. | Option exercise | 12K | $25.30 |
| 2025-09-30 | Khattar Jack A. | Sell | 8.6K | $48.25 |
| 2025-09-29 | Khattar Jack A. | Option exercise | 14K | $25.30 |
| 2025-09-29 | Khattar Jack A. | Sell | 10K | $48.02 |
| 2025-09-25 | Rubin Jonathan | Tax withheld | 840 | $46.21 |
| 2025-09-25 | Rubin Jonathan | Option exercise | 1.9K | — |
| 2025-09-23 | Khattar Jack A. | Option exercise | 48K | $12.98 |
| 2025-09-23 | Khattar Jack A. | Sell | 30K | $47.23 |
| 2025-09-22 | Khattar Jack A. | Option exercise | 27K | $12.98 |
| 2025-09-22 | Khattar Jack A. | Sell | 17K | $47.02 |
| 2025-09-12 | Mottola Frank | Option exercise | 5.0K | $39.40 |
| 2025-09-12 | Mottola Frank | Sell | 5.0K | $45.87 |
| 2025-09-08 | Khattar Jack A. | Option exercise | 8.1K | $25.30 |
| 2025-09-08 | Khattar Jack A. | Sell | 6.3K | $46.29 |
| 2025-09-05 | Khattar Jack A. | Sell | 56K | $46.01 |
| 2025-09-05 | Khattar Jack A. | Option exercise | 73K | $25.30 |
| 2025-08-28 | Khattar Jack A. | Option exercise | 39K | $12.98 |
| 2025-08-28 | Khattar Jack A. | Sell | 24K | $45.12 |
| 2025-08-27 | NEWHALL CHARLES W III | Sell | 3.6K | $45.01 |
| 2025-08-27 | Khattar Jack A. | Option exercise | 17K | $12.98 |
| 2025-08-27 | Khattar Jack A. | Sell | 11K | $45.05 |
| 2025-08-25 | Khattar Jack A. | Sell | 1.0K | $45.00 |
| 2025-08-25 | Mottola Frank | Option exercise | 14K | $12.98 |
| 2025-08-25 | Mottola Frank | Sell | 14K | $44.51 |
| 2025-08-25 | Khattar Jack A. | Option exercise | 1.6K | $12.98 |
| 2025-08-25 | Bhatt Padmanabh P. | Option exercise | 1.2K | — |
| 2025-08-25 | Bhatt Padmanabh P. | Tax withheld | 581 | $41.46 |
| 2025-08-25 | NEWHALL CHARLES W III | Sell | 1.0K | $45.00 |
| 2025-08-22 | Khattar Jack A. | Option exercise | 2.4K | $12.98 |
| 2025-08-22 | Khattar Jack A. | Sell | 1.5K | $45.00 |
| 2025-08-22 | DEC TIMOTHY C | Sell | 12K | $44.49 |
| 2025-08-22 | NEWHALL CHARLES W III | Sell | 1.4K | $45.00 |
| 2025-08-14 | Sensenig Bethany | Sell | 5.4K | $42.25 |
| 2025-08-14 | Hudson Frederick M. | Sell | 7.5K | $42.26 |
| 2025-08-06 | Khattar Jack A. | Option exercise | 60K | $12.98 |
| 2025-08-06 | Khattar Jack A. | Sell | 38K | $40.24 |
| 2025-08-06 | Khattar Jack A. | Option exercise | 60K | $12.98 |
| 2025-08-06 | Khattar Jack A. | Sell | 38K | $42.00 |
| 2025-08-06 | Khattar Jack A. | Option exercise | 81K | $25.30 |
| 2025-08-06 | Khattar Jack A. | Sell | 64K | $43.12 |
| 2025-04-02 | Khattar Jack A. | Other | 17K | — |
| 2025-04-02 | Khattar Jack A. | Other | 17K | — |
| 2025-03-10 | Khattar Jack A. | Option exercise | 35K | — |
| 2025-03-10 | Khattar Jack A. | Tax withheld | 17K | $32.06 |
| 2025-03-10 | DEC TIMOTHY C | Option exercise | 2.0K | — |
| 2025-03-10 | DEC TIMOTHY C | Tax withheld | 1.1K | $32.06 |
| 2025-03-10 | DEC TIMOTHY C | Option exercise | 1.8K | — |
| 2025-03-10 | DEC TIMOTHY C | Tax withheld | 955 | $32.06 |
| 2025-03-07 | Khattar Jack A. | Tax withheld | 19K | $39.11 |
| 2025-03-07 | Khattar Jack A. | Option exercise | 39K | — |
| 2025-03-07 | Mottola Frank | Option exercise | 2.6K | — |
| 2025-03-07 | Mottola Frank | Tax withheld | 1.4K | $39.11 |
| 2025-03-05 | DEC TIMOTHY C | Tax withheld | 1.3K | $33.05 |
| 2025-03-05 | DEC TIMOTHY C | Tax withheld | 276 | $33.05 |
| 2025-03-05 | Bhatt Padmanabh P. | Tax withheld | 575 | $33.05 |
| 2025-03-05 | Mottola Frank | Tax withheld | 337 | $33.05 |
| 2025-03-05 | Mottola Frank | Tax withheld | 610 | $33.05 |
| 2025-03-05 | Mottola Frank | Tax withheld | 945 | $33.05 |
| 2025-03-05 | Rubin Jonathan | Tax withheld | 314 | $33.05 |
| 2025-03-05 | Rubin Jonathan | Tax withheld | 577 | $33.05 |
| 2025-03-05 | Rubin Jonathan | Tax withheld | 577 | $33.05 |
| 2025-03-05 | DEC TIMOTHY C | Tax withheld | 1.6K | $33.05 |
| 2025-03-05 | Bhatt Padmanabh P. | Tax withheld | 335 | $33.05 |
| 2025-03-05 | Bhatt Padmanabh P. | Tax withheld | 575 | $33.05 |
| 2025-02-26 | Mottola Frank | Tax withheld | 976 | $39.48 |
| 2025-02-26 | Mottola Frank | Option exercise | 3.8K | — |
| 2025-02-26 | Mottola Frank | Tax withheld | 1.9K | $39.48 |
| 2025-02-26 | Mottola Frank | Option exercise | 2.0K | — |
| 2025-02-23 | DEC TIMOTHY C | Grant | 2.5K | — |
| 2025-02-23 | Mottola Frank | Grant | 1.9K | — |
| 2025-02-23 | Bhatt Padmanabh P. | Grant | 1.2K | — |
| 2025-02-23 | Rubin Jonathan | Grant | 1.2K | — |
| 2025-02-22 | Mottola Frank | Grant | 750 | — |
| 2025-02-22 | Bhatt Padmanabh P. | Grant | 750 | — |
| 2025-02-22 | Bhatt Padmanabh P. | Grant | 1.2K | — |
| 2025-02-22 | Rubin Jonathan | Grant | 750 | — |
| 2025-02-22 | Rubin Jonathan | Grant | 1.2K | — |
| 2025-02-22 | Mottola Frank | Grant | 1.2K | — |
| 2025-02-22 | DEC TIMOTHY C | Grant | 500 | — |
| 2025-02-22 | DEC TIMOTHY C | Grant | 3.0K | — |
| 2025-02-22 | Hudson Frederick M. | Grant | 5.4K | — |
| 2025-02-22 | NEWHALL CHARLES W III | Grant | 5.4K | — |
| 2025-02-22 | GEMAYEL GEORGES | Grant | 5.4K | — |
| 2025-02-22 | Barlow Carrolee | Grant | 5.4K | — |
| 2025-02-22 | Sensenig Bethany | Grant | 5.4K | — |
| 2025-02-21 | Bhatt Padmanabh P. | Option exercise | 1.6K | — |
| 2025-02-21 | Rubin Jonathan | Sell | 927 | $39.15 |
| 2025-02-21 | Mottola Frank | Option exercise | 1.1K | — |
| 2025-02-21 | Mottola Frank | Tax withheld | 552 | $39.15 |
| 2025-02-21 | Rubin Jonathan | Option exercise | 1.9K | — |
| 2025-02-21 | Bhatt Padmanabh P. | Tax withheld | 860 | $39.15 |
| 2025-02-04 | Bhatt Padmanabh P. | Sell | 9.5K | $39.70 |
| 2025-02-04 | Bhatt Padmanabh P. | Option exercise | 9.5K | $29.61 |
| 2025-01-28 | Bhatt Padmanabh P. | Option exercise | 700 | $29.61 |
| 2025-01-28 | Bhatt Padmanabh P. | Sell | 700 | $39.62 |
| 2025-01-27 | Bhatt Padmanabh P. | Sell | 2.6K | $39.62 |
| 2025-01-27 | Bhatt Padmanabh P. | Option exercise | 2.6K | $29.61 |
| 2025-01-22 | Hudson Frederick M. | Option exercise | 20K | $9.13 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07141329 ↗ | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures Focal Onset Seizures | PHASE2 | Recruiting | 2027-12-31 |
| NCT05518578 ↗ | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy Epilepsy, Seizures, Epileptic | PHASE2 | Recruiting | 2027-12-31 |
| NCT06798896 ↗ | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures Focal Onset Seizures | PHASE2 | Recruiting | 2027-08-01 |
| NCT07219927 ↗ | Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: Parkinson Disease | — | Recruiting | 2027-08-01 |
| NCT07226661 ↗ | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder Major Depressive Disorder (MDD) | PHASE2 | Recruiting | 2026-12-31 |
| NCT03474770 ↗ | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures Focal Impaired Awareness Seizures | PHASE1/PHASE2 | Active Not Recruiting | 2026-12-30 |
| NCT02736656 ↗ | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) Attention-Deficit/Hyperactivity Disorder | PHASE3 | Active Not Recruiting | 2026-09-01 |
| NCT04781140 ↗ | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD Attention-Deficit/Hyperactivity Disorder | PHASE4 | Recruiting | 2026-06-01 |
| NCT02339064 ↗ | Infusion of Apomorphine: Long-term Safety Study Idiopathic Parkinson's Disease | PHASE3 | Active Not Recruiting | 2018-12-01 |
| NCT05655520 ↗ | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease Huntington's Disease | PHASE3 | Terminated | 2025-01-20 |
| NCT06185985 ↗ | Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms Attention-Deficit/Hyperactivity Disorder | PHASE4 | Completed | 2024-12-03 |
| NCT05107128 ↗ | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) Huntington's Disease | PHASE2 | Completed | 2024-09-04 |
| NCT05619692 ↗ | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) Mild Cognitive Impairment, Mild Dementia | PHASE2 | Completed | 2024-06-05 |
| NCT05358821 ↗ | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease Huntington Disease | PHASE2 | Completed | 2024-02-29 |
| NCT05318937 ↗ | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment Parkinson Disease, Cognitive Dysfunction | PHASE2 | Completed | 2024-01-17 |
| NCT05645432 ↗ | An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus Tinnitus | PHASE2 | Completed | 2023-11-21 |
| NCT06259331 ↗ | Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women Healthy Lactating Women | PHASE4 | Completed | 2023-09-20 |
| NCT04786990 ↗ | Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) | PHASE4 | Completed | 2023-05-23 |
| NCT04050293 ↗ | Therapy for Migraine Prevention in Children 6-11 Years of Age Migraine Disorders, Headache Disorders | PHASE4 | Terminated | 2023-03-01 |
| NCT04143217 ↗ | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD Attention-Deficit/Hyperactivity Disorder | PHASE3 | Completed | 2022-07-26 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-18 | Shareholder voteExhibits | filing ↗ |
| 2026-05-20 | Debt obligationExhibits | filing ↗ |
| 2026-05-05 | ResultsExhibits | filing ↗ |
| 2026-04-22 | Results | filing ↗ |
| 2026-04-07 | Material agreementAcquisition/dispositionExhibits | filing ↗ |
| 2026-02-24 | ResultsExhibits | filing ↗ |
| 2026-02-24 | Exec/director changeExhibits | filing ↗ |
| 2026-02-12 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-18 | 0001356576-26-000028 ↗ |
| 8-K | 2026-05-20 | 2026-05-17 | 0001356576-26-000025 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001356576-26-000022 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001356576-26-000020 ↗ |
| 8-K | 2026-04-22 | 2026-04-22 | 0001356576-26-000015 ↗ |
| 8-K | 2026-04-07 | 2026-04-01 | 0001104659-26-040497 ↗ |
| 10-K | 2026-03-02 | 2025-12-31 | 0001356576-26-000011 ↗ |
| 8-K | 2026-02-24 | 2026-02-24 | 0001356576-26-000007 ↗ |
| 8-K | 2026-02-24 | 2026-02-24 | 0001356576-26-000004 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001356576-26-000002 ↗ |
| 8-K | 2026-01-28 | 2026-01-28 | 0001628280-26-003907 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001356576-25-000071 ↗ |